Atara Biotherapeutics, Inc. (ATRA) AI Dilution Summary

Estimated cash was $9,873,000 as of 2026-06-30, against estimated monthly burn of $1,112,667. The company's funding channel is its active ATM program with TD Securities (USA) LLC (as successor to Cowen and Company, LLC), authorised to $100,000,000, with $20,700,000 sold to date. Dilution here is driven primarily by that ATM's $79,300,000 of remaining capacity.